EpiCept Reports Second Quarter 2012 Operating and Financial Results
CONFERENCE CALL BEGINS AT 9:00 A.M. EASTERN TIME TODAY
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today reported net income of $3.0 million for the three months ended
June 30, 2012 and a reduced net loss for the six months ended June 30,
2012 to $0.6 million, primarily as a result of the Company's sale of its
Ceplene®-related assets and contract rights to Meda AB. The
net loss for the three and six month periods ended June 30, 2011 was
$4.3 million and $6.8 million, respectively. The Company also provided
an update on the Company's key business initiatives.
"EpiCept achieved an important strategic goal during the second quarter
of 2012 by completing the sale of our rights to Ceplene® for
Europe and several Asia Pacific countries to Meda," remarked Jack
Talley, President and Chief Executive Officer. "We pursued this course
of action after concluding that for at least the next several years
Ceplene® is unlikely to generate sufficient revenue for us to
fund the ongoing post-approval trial and the requirements for product
manufacturing. By completing the transaction with Meda we not only
received cash to help fund our ongoing operations, but we also freed
ourselves of millions of dollars of future Ceplene obligations that we
would have had to fund via additional debt or equity financing.
Additionally we have implemented several initiatives in terms of reduced
head count and other operating activities to reduce our cash burn as
evidenced in the year to year comparisons."
Business Highlights
-
Sold all rights to Ceplene® in the territories previously
licensed to Meda AB, and a portion of its remaining Ceplene®
inventory, to Meda for approximately $2.6 million in net cash and the
assumption of EpiCept's ongoing responsibilities related to the
manufacture of and maintenance of the marketing authorization for
Ceplene® in the European Union.
-
Received written advice from the Committee for Medicinal Products for
Human Use (CHMP) of the European Medicines Agency (EMA) in June
concerning the clinical and nonclinical development and subsequent
Marketing Authorization Approval (MAA) filing of AmiKet™ for the
treatment of chemotherapy-induced peripheral neuropathy (CIPN) that
was broadly consistent with guidance received from the FDA earlier
this year.
-
Granted Fast Track Status by the U.S. Food and Drug Administration
(FDA) for AmiKet™ for the treatment of CIPN. The FDA's Fast Track
program is designed to facilitate the development and expedite the
review of drugs intended to treat serious or life-threatening
conditions and address unmet medical needs. Fast Track may reduce the
standard review time of a New Drug Application by half.
-
New preclinical research for the licensed apoptosis inhibitor drug
candidate F573 (previously named EP1013) concluded that F573 is a new
therapeutic drug candidate for the treatment of late-stage viral
infection-induced hepatitis. The data were published in the Chinese
Pharmacological Bulletin (2102 Volume 28 (1):136-139). F573 was
discovered by EpiCept and licensed to GNI Group Ltd. in 2008 for
clinical development in Asia, Australia and New Zealand.
Product Portfolio Update
-
Ceplene® - approved in the EU and Israel for administration
with low-dose interleukin-2 (IL-2) for the remission maintenance and
prevention of relapse of patients with Acute Myeloid Leukemia (AML) in
first remission; AML is the deadliest form of leukemia in adults. In
June 2012, the Company sold all of its rights to Ceplene®
in the territories previously licensed to Meda AB, and a portion of
its remaining Ceplene® inventory, to Meda for approximately
$2.6 million in cash and the assumption of EpiCept's ongoing
responsibilities related to the manufacture of, and maintenance of the
marketing authorization for, Ceplene® in the European
Union. EpiCept also agreed to relinquish all future milestone payments
and royalties on future sales of Ceplene® by Meda. In
conjunction with the closing of this transaction EpiCept will close
its EpiCept GmbH facility in Munich, Germany over the next several
months. Ceplene® is licensed to Megapharm Ltd. to market
and sell in Israel. Following Ministry of Health approval of labeling
and other reimbursement matters expected this year, Megapharm Ltd. is
expected to commence the commercial launch of Ceplene® in
Israel, until which time it is available there on a named-patient
basis. EpiCept retains rights to Ceplene® in all other
countries, including countries in North and South America.
-
AmiKet™ - a prescription topical analgesic cream designed to provide
long-term relief from the pain of peripheral neuropathies, which
affect more than 15 million people in the U.S. alone. During the
second quarter of 2012, EpiCept received written advice from the
Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA) concerning the clinical and nonclinical
development and subsequent Marketing Authorization Approval (MAA)
filing of AmiKet™. In its written advice the CHMP recommended that the
proposed clinical program consist of a single 12-week, four-arm,
factorial-designed trial in CIPN that would seek to demonstrate
AmiKet™'s superiority compared with placebo and with each of the
component drugs of AmiKet™, amitriptyline and ketamine. An additional
two-arm efficacy study in CIPN or another neuropathy is required to
complete the clinical requirements of the application. The advice
provided a summary of the additional nonclinical program requirements
to file an MAA, which included a 90-day dermal toxicity study in a
non-rodent species, a dermal phototoxicity study in a rodent and an
ocular toxicity study. The advice received from the CHMP is consistent
with the guidance given to the Company by the FDA in January 2012, in
which the FDA waived several expensive and time-consuming non-clinical
toxicology studies, and indicated that a single four-arm factorial
trial might suffice for regulatory approval if combined with other
pivotal data in another neuropathy such as diabetic peripheral
neuropathy. The FDA granted Fast Track Status to AmiKet™ in April 2012
and has agreed that a Special Protocol Assessment (SPA) would be
available upon formal submission and agreement on the Phase III trial
protocol.
In addition to the positive outcome previously
reported for AmiKet™ in CIPN, EpiCept has reported statistically
significant positive results in the treatment of pain from
post-herpetic neuralgia in several Phase II studies, the
non-inferiority of AmiKet™ compared with gabapentin in another placebo
controlled study and a positive trend in the treatment of pain in a
diabetic neuropathy Phase II study.
-
F573 (previously known as EP1013) - a di-peptide small-molecule
compound licensed by EpiCept to GNI Group Ltd. in China, Japan and
other key Asian territories that has demonstrated a potent inhibitory
effect on caspases, a class of enzymes involved in cell death and
inflammation. Drug efficacy has been shown in animal models relating
to liver failure, brain ischemia and myocardial infarction. Data
published in the Chinese Pharmacological Bulletin (2102 Volume 28
(1):136-139) during the first quarter of 2012 concluded that F573 is a
new therapeutic drug candidate for the treatment of late-stage viral
infection-induced hepatitis. F573 delivered intravenously demonstrated
a therapeutic effect in a study involving 60 mice with acute liver
injury, including a reduction in TNF-a and cell apoptosis. As
part of its license agreement with GNI Group Ltd., EpiCept received a
small upfront fee upon signing the agreement and is eligible to
receive milestone payments of more than $12 million based on the
clinical advancement of F573 in in the licensed territories, as well
as royalties on commercial sales. EpiCept retains the commercial
rights to F573/EP1013 in all other markets. The next potential
milestone payment will be in conjunction with initiation of a Phase I
trial in any of the territories outlined in the agreement. In July
2011 Shanghai Genomics, a wholly owned subsidiary of GNI Group Ltd.,
filed an Investigational New Drug (IND) application for F573 in China.
-
CrolibulinTM - a vascular disruption agent that has
demonstrated potent anti-tumor activity in both preclinical and early
clinical studies. In December 2010 the NCI initiated a Phase Ib/II
trial with crolibulinTM to assess safety and efficacy in
combination with cisplatin in patients with anaplastic thyroid cancer.
Trial enrollment has progressed to the third and final dosing cohort
for the Phase Ib portion of this trial. The Phase II randomized
proof-of-concept efficacy portion of the trial is anticipated to begin
later in 2012.
-
Azixa™* - a vascular disruption agent discovered by EpiCept and
licensed to Myrexis, Inc. as part of an exclusive, worldwide
development and commercialization agreement. Azixa ™ has received
orphan drug status in the U.S. for the treatment of glioblastoma
multiforme. In February 2012 Myrexis suspended development activities
of all its preclinical and clinical programs in oncology and
autoimmune diseases, and in May 2012 the company stated that it is
focused on the identification, evaluation and acquisition of
appropriate commercial-stage assets. EpiCept believes that in light of
its new strategic direction, Myrexis does not intend to comply with
its development obligations; therefore, the Company intends to enforce
its rights under the license agreement with Myrexis.
Financial and Operating Highlights
EpiCept's net income attributable to common stockholders for the second
quarter of 2012 was $2.2 million, or $0.03 per diluted share, compared
with a net loss attributable to common stockholders of $4.3 million, or
$0.06 per share, for the second quarter of 2011. Net income attributable
to common stockholders for the second quarter of 2012 includes $0.8
million of deemed dividends on convertible preferred stock. EpiCept's
net loss attributable to common stockholders for the six months ended
June 30, 2012 was $2.5 million, or $0.03 per share, compared with a net
loss of $6.8 million, or $0.10 per share, for the six months ended June
30, 2011. The net loss attributable to common stockholders for the six
months ended June 30, 2012 includes $1.9 million of deemed dividends on
convertible preferred stock.
Second Quarter and Six Months 2012 vs. Second Quarter and Six Months
2011
Revenue
The Company recognized revenue of $6.6 million during the second quarter
of 2012, compared with $0.2 million during the second quarter of 2011.
The Company recognized revenue of $6.8 million during the six months
ended June 30, 2012, compared with $0.5 million during the six months
ended June 30, 2011. For the second quarter of 2012, revenue consisted
primarily of license fee payments and product revenue from the sale of
the Company's rights to Ceplene® to Meda AB. For the second
quarter of 2011, revenue consisted primarily of the recognition of
license fee payments previously received from strategic alliances.
Cost of Goods Sold
Cost of goods sold in the second quarter of 2012 consisted solely of the
costs from the sale of Ceplene® to Meda AB. Cost of goods
sold in the second quarter of 2011 consisted primarily of a $0.3 million
expense for Ceplene® inventory the Company believed would not
be sold prior to reaching its product expiration date. Cost of goods
sold was $0.4 million for each of the six months ended June 30, 2012 and
2011.
Selling, General and Administrative (SG&A) Expense
SG&A expense in the second quarter of 2012 decreased by approximately
30%, or $0.6 million, to $1.4 million, compared with $2.0 million
in the second quarter of 2011. The decrease was primarily attributable
to lower legal expenses, lower salary and salary related expenses as the
result of a reduction in projected bonus payments for 2012 and lower
investor relations expenses. SG&A expense for the six months ended June
30, 2012 decreased by approximately 18%, or $0.6 million, to $2.8
million, compared with $3.4 million for the six months ended June
30, 2011. Selling expense has been significantly reduced, and the
Company expects general and administrative expenses to remain at
approximately current levels over the next few quarters.
Research and Development (R&D) Expense
R&D expense in the second quarter of 2012 decreased by 50%, or $1.0
million, to $1.0 million from $2.0 million in the second quarter of
2011. R&D expense for the six months ended June 30, 2012 decreased by
approximately 38%, or $1.4 million, to $2.3 million, compared
with $3.7 million for the six months ended June 30, 2011. The decrease
was primarily attributable to lower clinical trial costs for Ceplene®,
lower salary and salary related expenses and lower patent expenses. Our
clinical efforts during the second quarters of 2012 and 2011 were
focused on our open label trial of Ceplene® that is intended
to meet our post-approval requirements with the EMA. . We expect
research and development expenses to remain at approximately current
levels over the next few quarters.
Other Income (Expense)
Other income (expense) during the second quarter of 2012 was net expense
of $0.9 million, compared with net expense of $0.3 million in the second
quarter of 2011. Other expense for the six months ended June 30, 2012
was $1.9 million, compared with other income of $0.2 million for the six
months ended June 30, 2011. The primary components of other expense in
2012 were warrant amendment expense of $0.9 million, interest expense of
$0.7 million related primarily to the Company's senior secured term loan
and a foreign exchange loss. Other income, net for the six months ended
June 30, 2011 was impacted by a $0.7 million foreign exchange gain
incurred as a result of the decreased value of the U.S. dollar compared
with the euro, which was partially offset by interest expense of $0.5
million.
Liquidity
EpiCept had $4.8 million in cash and cash equivalents as of June 30,
2012. The Company engaged SunTrust Robinson Humphrey in January 2012 to
assist in exploring strategic alternatives to maximize the commercial
opportunity of AmiKet™ for the treatment of CIPN following taxane-based
therapy. The engagement is focused on the identification and
implementation of a strategy designed to optimize AmiKet™'s value for
the Company's stockholders, which includes the evaluation of potential
transactions involving the sale of the Company. EpiCept is considering
various transactions to obtain additional cash resources to fund
operations and clinical trials, including the sale or licensing of
assets and the sale of equity securities. Current cash is anticipated to
be sufficient to run operations into the fourth quarter of 2012. If
EpiCept is unable to complete a transaction or otherwise obtain funding
on a timely basis, the Company may be forced to further reduce expenses
or curtail operations. See our Quarterly Report on Form 10-Q for the
period ended June 30, 2012 for a further discussion of the Company's
liquidity and cash position.
Conference Call
EpiCept will host a conference call to discuss these results and answer
questions on August 8, 2012 beginning at 9:00 a.m. Eastern time.
To participate in the live call, please dial from the United States or
Canada (877) 809-8594 or from international locations (706) 758-9407
(please reference access code 17527052). The conference call will also
be broadcast live in listen-only mode on the Internet and may be
accessed at www.epicept.com.
The webcast will be archived for 90 days.
A telephone replay of the call will be available for seven days by
dialing from the United States or Canada (855) 859-2056 or from
international locations (404) 537-3406 (please reference reservation
number 17527052).
About EpiCept Corporation
EpiCept is focused on the development and commercialization of
pharmaceutical products for the treatment of pain and cancer. The
Company's pain portfolio includes AmiKet™, a prescription topical
analgesic cream in late-stage clinical development designed to provide
effective long-term relief of pain associated with peripheral
neuropathies. The Company's product Ceplene®, when used
concomitantly with low-dose IL-2 is intended as remission maintenance
therapy in the treatment of AML for adult patients who are in their
first complete remission. The Company sold all of its rights to Ceplene®
in Europe and certain Pacific Rim countries and a portion of its
remaining Ceplene® inventory to Meda AB in June 2012. Ceplene®
is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept
has retained its rights to Ceplene® in all other countries,
including countries in North and South America. The Company has other
oncology drug candidates in clinical development that were discovered
using in-house technology and have been shown to act as vascular
disruption agents in a variety of solid tumors.
Forward-Looking Statements
This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
which express plans, anticipation, intent, contingency, goals, targets,
future development and are otherwise not statements of historical fact.
These statements are based on our current expectations and are subject
to risks and uncertainties that could cause actual results or
developments to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Factors that may cause actual results or developments to
differ materially include: the risks associated with the adequacy of our
existing cash resources and our ability to continue as a going concern,
the risks associated with our ability to continue to meet our
obligations under our existing debt agreements, the risk that Azixa™
will not receive regulatory approval or achieve significant commercial
success, the risk that we will not receive any significant payments
under our agreement with Myrexis, the risk that clinical trials for
AmiKet™ or crolibulinTM will not be successful, the risk that
AmiKet™ or crolibulinTM will not receive regulatory approval
or achieve significant commercial success, the risk that we will not be
able to find a partner to help conduct the Phase III trials for AmiKet™
on attractive terms, a timely basis or at all, the risk that Ceplene®
will not receive regulatory approval or marketing authorization in the
United States or Canada, the risk that Ceplene® will not
achieve significant commercial success, the risk that our other product
candidates that appeared promising in early research and clinical trials
do not demonstrate safety and/or efficacy in larger-scale or later-stage
clinical trials, the risk that we will not obtain approval to market any
of our product candidates, the risks associated with dependence upon key
personnel, the risks associated with reliance on collaborative partners
and others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our
history of operating losses since our inception; the highly competitive
nature of our business; risks associated with litigation; and risks
associated with our ability to protect our intellectual property. These
factors and other material risks are more fully discussed in our
periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and
other filings with the U.S. Securities and Exchange Commission. You are
urged to carefully review and consider the disclosures found in our
filings which are available at www.sec.gov
or at www.epicept.com.
You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be wrong due to inaccurate
assumptions, unknown risks or uncertainties or other risk factors.
Selected financial information follows:
|
EpiCept Corporation and Subsidiaries
|
|
(Unaudited)
|
|
Selected Consolidated Balance Sheet Data
|
|
(in $000s)
|
|
|
|
June 30,
|
|
December 31,
|
|
|
|
2012
|
|
2011
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
4,773
|
|
|
$
|
6,378
|
|
|
Inventory
|
|
|
6
|
|
|
|
360
|
|
|
Property and equipment, net
|
|
|
84
|
|
|
|
120
|
|
|
Total assets
|
|
$
|
5,302
|
|
|
$
|
7,521
|
|
|
|
|
|
|
|
|
Accounts payable and other accrued liabilities
|
|
$
|
3,276
|
|
|
$
|
3,333
|
|
|
Deferred revenue
|
|
|
8,700
|
|
|
|
12,947
|
|
|
Notes and loans payable
|
|
|
5,630
|
|
|
|
8,022
|
|
|
Total stockholders' deficit
|
|
|
(12,557
|
)
|
|
|
(17,146
|
)
|
|
Total liabilities and stockholders' deficit
|
|
$
|
5,302
|
|
|
$
|
7,521
|
|
|
EpiCept Corporation and Subsidiaries
|
|
(Unaudited)
|
|
Selected Consolidated Statement of Operations Data
|
|
(in $000s except share and per share data)
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
|
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
Product net revenues
|
|
$
|
577
|
|
|
$
|
1
|
|
|
$
|
583
|
|
|
$
|
1
|
|
|
Licensing and other revenues
|
|
|
6,025
|
|
|
|
223
|
|
|
|
6,260
|
|
|
|
461
|
|
|
Total net revenues
|
|
|
6,602
|
|
|
|
224
|
|
|
|
6,843
|
|
|
|
462
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Cost of product net revenues
|
|
|
396
|
|
|
|
270
|
|
|
|
396
|
|
|
|
360
|
|
|
Selling, general and administrative
|
|
|
1,384
|
|
|
|
2,042
|
|
|
|
2,815
|
|
|
|
3,436
|
|
|
Research and development
|
|
|
963
|
|
|
|
1,991
|
|
|
|
2,259
|
|
|
|
3,675
|
|
|
Total operating expenses
|
|
|
2,743
|
|
|
|
4,303
|
|
|
|
5,470
|
|
|
|
7,471
|
|
|
Income (loss) from operations
|
|
|
3,859
|
|
|
|
(4,079
|
)
|
|
|
1,373
|
|
|
|
(7,009
|
)
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
1
|
|
|
|
4
|
|
|
|
3
|
|
|
|
6
|
|
|
Foreign exchange (loss) gain
|
|
|
(521
|
)
|
|
|
155
|
|
|
|
(264
|
)
|
|
|
659
|
|
|
Warrant amendment expense
|
|
|
—
|
|
|
|
—
|
|
|
|
(936
|
)
|
|
|
—
|
|
|
Interest expense
|
|
|
(380
|
)
|
|
|
(422
|
)
|
|
|
(743
|
)
|
|
|
(461
|
)
|
|
Other income (expense), net
|
|
|
(900
|
)
|
|
|
(263
|
)
|
|
|
(1,940
|
)
|
|
|
204
|
|
|
Net income (loss) before income taxes
|
|
|
2,959
|
|
|
|
(4,342
|
)
|
|
|
(567
|
)
|
|
|
(6,805
|
)
|
|
Income taxes
|
|
|
—
|
|
|
|
—
|
|
|
|
(2
|
)
|
|
|
(3
|
)
|
|
Net income (loss )
|
|
$
|
2,959
|
|
|
$
|
(4,342
|
)
|
|
$
|
(569
|
)
|
|
$
|
(6,808
|
)
|
|
Deemed dividends on convertible preferred stock
|
|
|
(750
|
)
|
|
|
—
|
|
|
|
(1,926
|
)
|
|
|
—
|
|
|
Income (loss) attributable to common stockholders
|
|
$
|
2,209
|
|
|
$
|
(4,342
|
)
|
|
$
|
(2,495
|
)
|
|
$
|
(6,808
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted income (loss) per common share
|
|
$
|
0.03
|
|
|
$
|
(0.06
|
)
|
|
$
|
(0.03
|
)
|
|
$
|
(0.10
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares - Basic
|
|
|
83,772,960
|
|
|
|
70,993,924
|
|
|
|
80,414,692
|
|
|
|
65,578,505
|
|
|
Weighted average shares - Diluted
|
|
|
91,591,893
|
|
|
|
70,993,924
|
|
|
|
80,414,692
|
|
|
|
65,578,505
|
|
|
EpiCept Corporation and Subsidiaries
|
|
(Unaudited)
|
|
Selected Consolidated Statement of Cash Flows Data
|
|
(in $000s)
|
|
|
|
|
|
|
|
Six Months Ended June 30,
|
|
|
|
2012
|
|
2011
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
$
|
(2,599
|
)
|
|
$
|
(6,344
|
)
|
|
Net cash provided by investing activities
|
|
|
—
|
|
|
|
116
|
|
|
Net cash provided by financing activities
|
|
|
1,003
|
|
|
|
18,362
|
|
|
Effect of exchange rate changes on cash
|
|
|
(9
|
)
|
|
|
9
|
|
|
Net (decrease) increase in cash and cash equivalents
|
|
|
(1,605
|
)
|
|
|
12,143
|
|
|
Cash and cash equivalents at beginning of year
|
|
|
6,378
|
|
|
|
2,435
|
|
|
Cash and cash equivalents at end of year
|
|
$
|
4,773
|
|
|
$
|
14,578
|
|
|
EpiCept Corporation and Subsidiaries
|
|
(Unaudited)
|
|
Selected Consolidated Statement of Stockholders' Deficit Data
|
|
(in $000s)
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30,
|
|
|
|
2012
|
|
2011
|
|
|
|
|
|
|
|
Stockholders' deficit at beginning of year
|
|
$
|
(17,146
|
)
|
|
$
|
(14,135
|
)
|
|
|
|
|
|
|
|
Net loss for the period
|
|
|
(569
|
)
|
|
|
(6,808
|
)
|
|
Stock-based compensation expense
|
|
|
404
|
|
|
|
500
|
|
|
Foreign currency translation adjustment
|
|
|
257
|
|
|
|
(698
|
)
|
|
Share and warrant issuance
|
|
|
2,833
|
|
|
|
11,416
|
|
|
Warrant amendment expense
|
|
|
936
|
|
|
|
—
|
|
|
Exercise of warrants
|
|
|
728
|
|
|
|
—
|
|
|
|
|
|
|
|
|
Stockholders' deficit at end of year
|
|
$
|
(12,557
|
)
|
|
$
|
(9,725
|
)
|
EpiCept had 84,088,023 shares outstanding as of July 31, 2012. EpiCept
expects to release its interim results for the period ending September
30, 2012 on or about November 10, 2012.
# # #
*Azixa is a registered trademark of Myrexis, Inc.
EPCT-GEN
EpiCept Corporation:
Robert W. Cook, 914-606-3500
rcook@epicept.com
or
Media:
Feinstein
Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com
or
Investors:
LHA
Kim
Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce
Voss, 310-691-7100
bvoss@lhai.com
@LHA_IR_PR
Source: EpiCept Corporation
News Provided by Acquire Media
Close window | Back to top
